In the hunt for an antigen in solid tumors that CAR-T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
Researchers reported finding oncohistone mutations within nearly 4 percent of tumors and said they could alter the structure and function of chromatin.
MSK's PathoMAN achieved 94 percent and 81 percent concordance with results from three commercial labs for pathogenic and benign variants, respectively.
In Nature this week: study of gene drive feasibility in lab mice, circulating tumor DNA from cerebrospinal fluid to track glioma progression, and more.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.
